SCHEMBL21767871

SCHEMBL21767871

COc1cccc(C2=CCN(C(=O)OC(C)(C)C)C2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK4 Q16654 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NAMPT P43490 2/20 0.43
ABL1 P00519 1/20 0.43
EGFR P00533 1/20 0.43
SRC P12931 1/20 0.43
ABL2 P42684 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MKNK1 Q9BUB5 1/20 0.42
MGAT2 Q10469 1/20 0.42
DGAT2 Q96PD7 1/20 0.42
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
GRM5 P41594 3/20 0.41
GRM1 Q13255 3/20 0.41
USP30 Q70CQ3 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ADAM10 O14672 1/20 0.40
MMP2 P08253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29941117 1.00 PDK4 (0.47) PDK4MEN1KMT2ANAMPTABL1
SCHEMBL21361618 0.88 MGAT2 (0.44) PDK4MEN1KMT2AABL1EGFR
SCHEMBL30952437 0.88 MGAT2 (0.44) PDK4MEN1KMT2AABL1EGFR
SCHEMBL6848748 0.88 PDK4 (0.55) PDK4MEN1KMT2ANAMPTGRM5
SCHEMBL29914770 0.88 PDK4 (0.55) PDK4MEN1KMT2ANAMPTGRM5
SCHEMBL21381680 0.87 PDK4 (0.44) PDK4NAMPTGRM5GRM1USP30
SCHEMBL30149826 0.87 PDK4 (0.44) PDK4NAMPTGRM5GRM1USP30
SCHEMBL22619074 0.85 PDK4 (0.48) PDK4NAMPTABL1EGFRSRC
SCHEMBL23510810 0.84 PDK4 (0.47) PDK4NAMPTGRM5GRM1USP30
SCHEMBL3648168 0.84 GRM5 (0.53) PDK4NAMPTMKNK1GRM5GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110573512-B Heterocyclic compounds 武田药品工业株式会社 2022-09-06 CN disclosed
US-10919891-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-02-16 US disclosed
US-10875862-B2 2020-12-29 US disclosed
US-20200131174-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-04-30 US disclosed
EP-3617209-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-03-04 EP disclosed
CN-110573512-A Heterocyclic compounds 武田药品工业株式会社 2019-12-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919891-B2 Heterocyclic compound CASR, AGTR2, AGTR1 PDK4 4139/4885MEN1 1763/4885KMT2A 2678/4885
US-20200131174-A1 HETEROCYCLIC COMPOUND CASR, AGTR2, AGTR1 PDK4 4139/4885MEN1 1763/4885KMT2A 2678/4885
US-10875862-B2 CASR, AGTR2, AGTR1 PDK4 4431/4885MEN1 2648/4885KMT2A 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.